Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 anti-BCMA CAR T cell therapy - Suzhou Maximum Bio-tech

Next Previous
Drug Profile

Anti-CD19 anti-BCMA CAR T cell therapy - Suzhou Maximum Bio-tech

Alternative Names: Anti-CD19-anti-BCMA chimeric antigen receptor T cell therapy - Suzhou Maximum Bio-tech; CD19-BCMA chimeric antigen receptor T cell therapy - Suzhou Maximum Bio-tech

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Maximum Bio-tech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral, Infusion)
  • 01 Jan 2020 Suzhou Maximum Bio-tech plans a phase I trial for Multiple myeloma (Late-stage disease, Second-line therapy or greater) in China
  • 27 Dec 2019 Preclinical trials in Multiple myeloma in China (Parenteral) before December 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top